Diabetic neuropathy (DN) is a debilitating disorder that occurs in nearly 50 percent of patients with diabetes, causing motor deficits, silent cardiac ischemia, orthostatic hypotension, vasomotor instability, hyperhidrosis, gastroparesis, bladder dysfunction, and sexual dysfunction. The objective of his short communication was to provide an insightful overview of prevention of diabetic peripheral neuropathy (DPN), a common disabling microvascular complication of diabetes and its associated foot complications. Glycemic control is an essential intervention shown to be beneficial in both type-1 and type-2 diabetes patients in preventing microvascular and neuropathic foot complications. Medical management comprising of acetyl-L-carnitine, Aldose reductase inhibitors, antioxidants, essential fatty acids, chromium, ginkgolides, and pentoxifylline, Ciliary neurotrophic factor, coenzyme Q10, edaravone, Erythropoietin and its carbamylated derivative, gamma linolenic acid, gangliosides, GCPII (NAALADase) inhibitor, glutathione, IGF1, methylcobalamin, Olive (Oleaeuropaea L.) leaf extract, oxygen supplementation and Tolrestat (Giugliano et al, 1995) were reported for preventing DPN. Flexor tenotomy, insoles, Podikon digital silicone padding, tibial neurolysis, surgical decompression of lower extremity peripheral nerves were reported for their efficacy to prevent diabetes-related neuropathic foot complications. 

Keywords: Preventive medicine; Preventive endocrinology; Preventive neurology; Diabetic neuropathy; Primary and secondary prevention.